EHA 2024 | Intrathecal rituximab plus dexamethasone in B-cell malignancies with CNS involvement
Maher Salamoon, MD, Al-Baironi Hospital, Damascus, Syria, discusses a study investigating intrathecal rituximab plus dexamethasone in triple therapy refractory B-cell malignancies with central nervous system (CNS) involvement. Among 25 patients, primarily diagnosed with acute lymphoblastic leukemia (ALL), this combination achieved clear cerebrospinal fluid (CSF) in 66% after 4 cycles and 88% after 8 cycles. Common side effects like headaches were manageable. Dr Salamoon mentions plans for a future trial investigating rituximab-containing quadruplet therapy in ALL with CNS involvement. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
